Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to provide additional funding to Integrated Care Boards for the importation of alternative pancreatic enzyme replacement therapy brands.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department monitors and manages medicine supply issues at a national level so that stocks remain available to meet regional and local demand. Information on stock levels within individual National Health Service trusts is not held centrally.
The Department is continuing to engage with all suppliers of pancreatic enzyme replacement therapy (PERT) to mitigate the supply issue that is affecting the whole of the United Kingdom. Through this, we have managed to secure additional volumes of PERT for 2025 for the UK. We are continuing to work with all suppliers to understand what more can be done to add further resilience to the market. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market.
In the longer term, the Department has had interest from non-UK suppliers wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers, and if authorised, these products could further diversify and strengthen the market.
In December 2024, the Department issued further management advice to healthcare professionals. This directs clinicians to consider the unlicensed imports when licensed stock is unavailable and includes actions for integrated care boards to ensure local mitigation plans are put in place and implemented. The Department continues to collaborate closely with NHS England colleagues, clinicians, patient groups, and charities to ensure that these mitigation plans are supporting patients, and routinely updates advice and issues further guidance when necessary. There are no current plans to provide additional funding for unlicensed imports.
The Department will continue to meet with suppliers, clinicians, representatives from the impacted patient advocacy groups, and charities so that they are informed on the supply situation and the mitigation actions being taken.
Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to diversify the supply chain for pancreatic enzyme replacement therapy.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department monitors and manages medicine supply issues at a national level so that stocks remain available to meet regional and local demand. Information on stock levels within individual National Health Service trusts is not held centrally.
The Department is continuing to engage with all suppliers of pancreatic enzyme replacement therapy (PERT) to mitigate the supply issue that is affecting the whole of the United Kingdom. Through this, we have managed to secure additional volumes of PERT for 2025 for the UK. We are continuing to work with all suppliers to understand what more can be done to add further resilience to the market. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market.
In the longer term, the Department has had interest from non-UK suppliers wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers, and if authorised, these products could further diversify and strengthen the market.
In December 2024, the Department issued further management advice to healthcare professionals. This directs clinicians to consider the unlicensed imports when licensed stock is unavailable and includes actions for integrated care boards to ensure local mitigation plans are put in place and implemented. The Department continues to collaborate closely with NHS England colleagues, clinicians, patient groups, and charities to ensure that these mitigation plans are supporting patients, and routinely updates advice and issues further guidance when necessary. There are no current plans to provide additional funding for unlicensed imports.
The Department will continue to meet with suppliers, clinicians, representatives from the impacted patient advocacy groups, and charities so that they are informed on the supply situation and the mitigation actions being taken.
Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will bring forward legislative proposals to regulate the packaging of vapes to provide similar safeguards to that of cigarettes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
It is very worrying that approximately 25% of 11 to 15-year-olds have tried vaping, despite the risks of nicotine addiction. Evidence suggests that vapes appeal to children because of the brightly coloured packaging, amongst other child-friendly features. Evidence also indicates that the nicotine content descriptions on vape packaging are not consistent between packaging, preventing adults from making informed decisions on nicotine strength.
The Tobacco and Vapes Bill provides my Rt Hon. Friend, the Secretary of State for Health and Social Care with regulation-making powers to introduce new requirements on retail packaging, including for vaping products and nicotine products. There is a balance to be struck between reducing the appeal of vapes to non-smokers, particularly children, whilst considering the implications for adult smokers to ensure we can achieve the greatest possible impact.
It is our intention to regulate the appeal of vapes to children, whilst minimising the impact on adult smokers. We plan on consulting on the preferred options to get this balance right as soon as possible after the bill gains Royal Assent.
Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of workforce shortages on the delivery of palliative care services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The delivery of palliative and end of life care services is a devolved matter. We want to assure ourselves and the National Health Service in England that it has access to the workforce it needs in the years ahead to ensure that patients, including those at end of life, are cared for by the right professional, when and where they need it. We will need to do this in light of the 10-Year Health Plan.
In England, palliative and end of life care is wide-ranging, provided by generalist as well as specialist healthcare professionals, and is not disease/diagnosis specific. A large proportion of palliative and end of life care is not provided by palliative care specialists and, therefore, it is difficult to quantify the totality of the NHS workforce providing palliative and end of life care.
Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of changes made to employer National Insurance contributions at the Autumn Budget 2024 on access to palliative care.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The delivery of palliative and end of life care services is a devolved matter.
We have taken necessary decisions to fix the foundations in the public finances at the Autumn Budget, which enabled the Spending Review settlement of a £22.6 billion increase in resource spending for the Department from 2023/24 outturn to 2025/26. The employer National Insurance contributions rise will be implemented in April 2025.
In England, palliative care services are included in the list of services an integrated care board (ICB) must commission. This promotes a more consistent national approach and supports commissioners in prioritising palliative and end of life care. To support ICBs in this duty, NHS England has published statutory guidance and service specifications.
Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure palliative care standards are maintained for an aging population.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The delivery of palliative and end of life care services is a devolved matter.
We have taken necessary decisions to fix the foundations in the public finances at the Autumn Budget, which enabled the Spending Review settlement of a £22.6 billion increase in resource spending for the Department from 2023/24 outturn to 2025/26. The employer National Insurance contributions rise will be implemented in April 2025.
In England, palliative care services are included in the list of services an integrated care board (ICB) must commission. This promotes a more consistent national approach and supports commissioners in prioritising palliative and end of life care. To support ICBs in this duty, NHS England has published statutory guidance and service specifications.
Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to paragraph 2.40 of the Autumn Budget 2024, HC 295, published on 30 October 2024, if he will make an assessment of the potential merits of providing additional support to (a) GP practices, (b) pharmacies and (c) dental services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We have taken necessary decisions to fix the foundations in the public finances at the Autumn Budget, which has enabled the Spending Review settlement of a £22.6 billion increase in resource spending for the Department from 2023/24 outturn to 2025/26. The employer National Insurance rise will be implemented April 2025, and the Department will set out further details on the allocation of funding for next year in due course.
Primary care providers, including general practice (GP), dentistry, pharmacy, and eye care, are valued independent contractors who provide nearly £20 billion worth of National Health Services. Every year we consult with each sector both about what services they provide, and the money providers are entitled to in return under their contract. As in previous years, this issue will be dealt with as part of that process.
We will shortly begin discussions on the annual GP Contract and on the funding arrangements for community pharmacy in 2025/26. I am unable to say more until these have been concluded.
Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle shortages of molybdenum-technetium generators.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working hard with industry to help resolve the shortages of radioisotopes, which are affecting the United Kingdom and other countries around the world. The affected radioisotopes are mainly used for diagnosing cancers, including prostate and breast cancer, and are also used for the imaging of organ function in scans, including for the heart. Supply of the affected molybdenum-technetium generators has improved significantly during week of 11 November.
The Department has worked in close partnership with National Health Service specialists from across the UK, suppliers, the British Nuclear Medicine Society, the UK Radiopharmacy Group, and the devolved administrations, including Scotland, to ensure that critical patients are prioritised, and that the limited supply is shared equitably between hospitals and trusts across the UK.
The Department issued a National Patient Safety alert which provided comprehensive management advice for NHS clinicians across the UK on how to manage and prioritise patients affected by these shortages. The guidance covers actions for health boards in the devolved nations, including on the coordination of mutual aid arrangements and escalation routes where issues are identified.
Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that suitable stockpiles of essential medications are available to the NHS to limit the effects of production shortages.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Whilst stock of a small number of medicines is held by the Government, for example as a result of COVID-19 preparedness, stockpiling essential medicines centrally is not a tool that the Department uses to limit the effects of production shortages. While we can’t always prevent supply issues from occurring, we have a range of well-established processes and tools to manage them when they do arise, to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, including pharmacists, so they can advise and support their patients.
Asked by: Susan Murray (Liberal Democrat - Mid Dunbartonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to Joint Committee on Vaccination and Immunisation statement on a childhood varicella (chickenpox) vaccination programme, published on 14 November 2023, if he will make an assessment of the potential merits of adding varicella vaccinations to the childhood immunisation programme.
Answered by Andrew Gwynne
The Joint Committee on Vaccination and Immunisation (JCVI) recommended a universal varicella, also known as chickenpox, vaccination programme be introduced as part of the routine childhood schedule. This recommendation was based on an assessment of the estimated programme cost-effectiveness as well as cases of severe varicella that could be prevented. The JCVI’s statement is available at the following link:
Ministers have accepted the JCVI’s recommendation, and the Department is in discussions with NHS England and the UK Health Security Agency on the potential implementation of the recommendation.